Vanguard Group Inc Rallybio Corp Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Rallybio Corp stock. As of the latest transaction made, Vanguard Group Inc holds 857,896 shares of RLYB stock, worth $952,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares

857,896

Previous 1,076,771 20.33%

Holding current value

$952,264

Previous $1.99 Million 42.32%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.34 - $2.98 $293,292 - $652,247	-218,875 Reduced 20.33%	857,896 $1.15 Million
Q1 2024 May 10, 2024	BUY	$1.25 - $2.4 $16,001 - $30,722	12,801 Added 1.2%	1,076,771 $1.99 Million
Q4 2023 Feb 14, 2024	BUY	$1.91 - $4.39 $27,005 - $62,070	14,139 Added 1.35%	1,063,970 $2.54 Million
Q3 2023 Nov 14, 2023	BUY	$3.37 - $6.16 $39,462 - $72,133	11,710 Added 1.13%	1,049,831 $3.54 Million
Q2 2023 Aug 14, 2023	BUY	$4.31 - $8.89 $185,765 - $383,167	43,101 Added 4.33%	1,038,121 $5.88 Million
Q1 2023 May 15, 2023	BUY	$4.37 - $8.75 $115,009 - $230,282	26,318 Added 2.72%	995,020 $5.68 Million
Q4 2022 Feb 10, 2023	BUY	$4.67 - $14.86 $794,208 - $2.53 Million	170,066 Added 21.29%	968,702 $6.36 Million
Q3 2022 Nov 14, 2022	BUY	$7.54 - $14.56 $770,037 - $1.49 Million	102,127 Added 14.66%	798,636 $11.6 Million
Q2 2022 Aug 12, 2022	SELL	$6.26 - $13.65 $84,760 - $184,821	-13,540 Reduced 1.91%	696,509 $5.26 Million
Q1 2022 May 13, 2022	BUY	$6.91 - $15.04 $2.7 Million - $5.87 Million	390,170 Added 121.97%	710,049 $4.96 Million
Q4 2021 Feb 14, 2022	SELL	$9.3 - $19.91 $658,551 - $1.41 Million	-70,812 Reduced 18.12%	319,879 $3.05 Million
Q3 2021 Nov 12, 2021	BUY	$10.83 - $23.4 $4.23 Million - $9.14 Million	390,691 New	390,691 $6.87 Million

Others Institutions Holding RLYB

# of Institutions

Shares Held

32.2M

Call Options Held

Put Options Held

View Full List

About Rallybio Corp

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $35.7M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

More about RLYB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Rallybio Corp Transaction History